

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, 15/52, C07K 14/78, 14/47, A61K 38/17, A01K 67/027	A1	(11) International Publication Number: WO 00/06729 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17147 (22) International Filing Date: 28 July 1999 (28.07.99) (30) Priority Data: 09/124,671 29 July 1998 (29.07.98) US (71) Applicant: SLOAN-KETTERING INSTITUTE FOR CAN- CER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US). (72) Inventors: ROTHMAN, James, E.; Apartment 10B, 402 E. 64th Street, New York, NY 10021 (US). MAYHEW, Mark; Apartment 3E, 414 Benedict Avenue, Tarrytown, NY 10591 (US). HOE, Mee, H.; Apartment 4C, 312 E. 66th Street, New York, NY 10021 (US). (74) Agents: CLARK, Richard, S. et al.; Baker & Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112-0228 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: KDEL RECEPTOR INHIBITORS (57) Abstract The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

KDEL RECEPTOR INHIBITORS

SPECIFICATION

1. INTRODUCTION

The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence at the protein carboxy terminus and a KDEL-binding receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.

2. BACKGROUND OF THE INVENTION

A living cell is a complex assembly of molecular elements; to function properly, its constituent molecules must form associations and operate in an organized manner. Certain components bind together to form molecular superstructures, including organelles which compartmentalize cellular activities and filaments which impart order and control motility. Other components exist in soluble form, and may move freely throughout the cell or, alternatively, within a subcellular compartment.

Cells are also equipped with elements that synthesize, process, and secrete a designated subset of proteins. This so-called secretory pathway includes membrane associated structures, such as the endoplasmic reticulum and Golgi apparatus, as well as a number of resident soluble molecules which participate in the processing of secreted proteins. Proteins which are to be secreted pass through the Golgi apparatus, where they are packaged for export from the cell. Accompanying them, by virtue of the continual vesicular transport of membrane and endoplasmic reticulum luminal contents, are soluble proteins properly residing in the endoplasmic

reticulum.

To avoid continuously losing and needing to resynthesize these resident proteins, the cell uses a membrane-bound receptor localized in or near the Golgi apparatus for their retrieval (Lewis and Pelham, 1992, Cell 68:353-364). The receptor binds to a specific carboxy-terminal amino acid sequence which serves as a marker of what proteins are to be returned to the endoplasmic reticulum; this sequence is generally lysine-aspartic acid-glutamic acid-leucine (Lys-Asp-Glu-Leu in the three-letter amino acid code, KDEL in the single-letter code, referred to herein as "KDEL"), so that the receptor is generally referred to as the KDEL receptor (Munro and Pelham, 1987, Cell 48:899-907; Pelham, 1988, EMBO J. 7:913-918). The human KDEL receptor has been characterized as a seven-transmembrane domain protein which is a temporary resident of the Golgi apparatus: upon binding to a KDEL-containing ligand, it moves to the endoplasmic reticulum, where the ligand is released (Townesley et al., 1993, EMBO J. 12:2821-2829).

Among the molecules interacting with the KDEL receptor are certain members of a class of proteins, referred to as "heat shock proteins", which form associations with nascent polypeptides in the endoplasmic reticulum and act as molecular "chaperones", escorting a protein through the assembly process prior to its secretion (Frydman et al., 1994, Nature 370:111-117; Hendrick and Hartl, Annu. Rev. Biochem. 62:349-384; Hartl, 1996, Nature 381:571-580). Heat shock proteins constitute a highly conserved class of proteins selectively expressed in cells under stressful conditions, such as sudden increases in temperature or glucose deprivation. Able to bind to a wide variety of other proteins in their non-native state, heat shock proteins participate in the manufacture of these bound proteins, including their synthesis, folding, assembly, disassembly and translocation (Freeman and Morimoto, 1996, EMBO J. 15:2969-2979; Lindquist and Craig, 1988, Annu. Rev. Genet. 22:631-677; Hendrick and Hartl, 1993, Annu. Rev. Biochem. 62:349-384).

Two heat shock proteins which contain ligand sequences for the KDEL receptor are gp96 and BiP. Found in higher eukaryotes but not in *Drosophila* or yeast, gp96 appears to have evolved relatively recently, perhaps by a duplication of the gene encoding the cytosolic heat shock protein hsp90, to which it is highly related (Li and

Srivastava, 1993, EMBO J. 12:3143-3151; identity between human hsp90 and murine gp96 is about 48 percent; Wiech et al., 1992, Nature 358:169-170; Melnick et al., 1992, J. Biol. Chem. 267:21303-21306; Melnick et al., 1994, Nature 370:373-375; Schaiff et al., 1992, J. Exp. Med. 176:657-666; Ramakrishnan et al., 1995, DNA and
5 Cell Biol. 14:373-384). BiP (also referred to in the literature as grp78) forms a complex with newly synthesized immunoglobulin chains (Bole et al., 1986, J. Cell Biol. 102:1558-1566).

Under certain circumstances, it may be desirable to interfere with the normal control of KDEL-mediated protein redistribution. According to the present
10 invention, a subject may benefit, for example, from the secretion of heat shock proteins which are normally retained in the endoplasmic reticulum but which have beneficial immunogenic effects when released.

Heat shock proteins are believed to play a role in the immune response in several contexts. Inoculation with heat shock protein prepared from tumors of
15 experimental animals has been shown to induce immune responses in a tumor-specific manner; that is to say, heat shock protein gp96 purified from a particular tumor could induce an immune response which would inhibit the growth of cells from the identical tumor of origin, but not other tumors, regardless of relatedness (Srivastava and Maki, 1991, Curr. Topics Microbiol. 167:109-123). High-resolution gel electrophoresis has
20 indicated that tumor-derived gp96 may be heterogeneous at the molecular level; evidence suggests that the source of this heterogeneity may be populations of small peptides adherent to the heat shock protein, which may number in the hundreds (Feldweg and Srivastava, 1995, Int. J. Cancer 63:310-314). Indeed, an antigenic peptide of vesicular stomatitis virus has been shown to associate with gp96 in virus
25 infected cells (Niemand et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:6135-6139). It has been suggested that this accumulation of peptides is related to the localization of gp96 in the endoplasmic reticulum, where it may act as a peptide acceptor and accessory to peptide loading of major histocompatibility complex class I molecules (Li and Srivastava, 1993, EMBO J. 12:3143-3151; Suto and Srivastava, 1995, Science
30 269:1585-1588). Recent studies have shown that protein disulfide isomerase ("PDI"), a resident luminal protein of the endoplasmic reticulum having a molecular weight of

approximately 60kDa, may also function as a peptide acceptor (Lammert et al., 1997, Eur. J. Immunol. 27:1685-1690).

Further, the use of heat shock proteins as adjuvants to stimulate an immune response has been proposed (see, for example, Edgington, 1995, Bio/Technol. 13:1442-1444; PCT Application International Publication Number WO 94/29459 by the Whitehead Institute for Biomedical Research, Richard Young, inventor, and references *infra*). One of the best known adjuvants, Freund's complete adjuvant, contains a mixture of heat shock proteins derived from mycobacteria (the genus of the bacterium which causes tuberculosis); Freund's complete adjuvant has been used for years to boost the immune response to non-mycobacterial antigens. A number of references suggest, *inter alia*, the use of isolated mycobacterial heat shock proteins for a similar purpose, including vaccination against tuberculosis itself (Lukacs et al., 1993, J. Exp. Med. 178:343-348; Lowrie et al., 1994, Vaccine 12:1537-1540; Silva and Lowrie, 1994, Immunology 82:244-248; Lowrie et al., 1995, J. Cell. Biochem. Suppl. 0(19b):220; Retzlaff et al., 1994, Infect. Immun. 62:5689-5693; PCT Application International Publication No. WO 94/11513 by the Medical Research Council, Colston et al., inventors; PCT Application International Publication No. WO 93/1771 by Biocine Sclavo Spa, Rappuoli et al., inventors).

Increased levels of autologous heat shock proteins may also lead to an improved immune response by virtue of the association of heat shock proteins with endogenous antigenic peptides (International Application No. PCT/US96/13233 by Rothman et al.). Such activity is distinct from the traditionally utilized adjuvant activity of heterologous heat shock proteins.

The present invention is directed toward increasing the secretion of antigenic heat shock protein complexes by inhibiting KDEL receptor-mediated return of such complexes to the endoplasmic reticulum. Analogous methods may be used to increase the secretion of other proteins of interest which normally would tend to be retained via the KDEL receptor.

3. SUMMARY OF THE INVENTION

The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. It is based, at least in part, on the ability of such inhibitors to promote the secretion of proteins which would otherwise tend to be retained in the cell in which they are produced.

In nonlimiting embodiments, the present invention provides for a protein comprising a plurality of amino acid sequences which bind to the KDEL receptor. Such an inhibitory protein, introduced into a cell, would promote the secretion of proteins which would otherwise tend to be functionally retained in the cell via interaction with the KDEL receptor. The secreted proteins may include proteins naturally produced by the cell and/or proteins expressed as a result of the introduction of nucleic acid encoding said proteins into the cell or a progenitor thereof. As specific, nonlimiting examples, the secretion of certain endogenous or exogenously introduced heat shock proteins may be promoted in this manner. Moreover, the KDEL receptor inhibitor protein may be introduced into a cell in conjunction with an antigenic peptide capable of associating with a heat shock protein, and used to promote the secretion of heat shock protein/antigenic peptide complexes.

In further embodiments, the present invention provides for the identification of further compounds, including peptomimetic compounds, which inhibit the association of a KDEL receptor with its protein ligands which may, for example, be prepared by combinatorial chemistry techniques or identified by phage display. Such compounds may be used in methods analogous to those described above to promote the secretion of certain proteins.

4. DESCRIPTION OF THE FIGURES

FIGURE 1. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (in this example, from mouse BiP); (ii) the oligomerization domain of rat cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number

of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein encoded by the construct depicted in (A) (SEQ ID NO:13), showing the cleavable leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDLA (from the rat COMP), the rat COMP pentamerization domain (overlined), and the camel IgG linker domain (underlined and overlined), linked to KDEL. (C-D) Nucleic acid sequence of the rat COMP-KDEL construct shown in (A) (SEQ ID NO:14).

FIGURE 2.(A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of rat cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein encoded by the construct depicted in (A) (SEQ ID NO:15), showing the cleavable leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased stability via disulfide bonds); the rat COMP pentamerization domain (overlined), and the camel IgG linker domain (underlined and overlined), linked to KDEL. (C- D) Nucleic acid sequence of the rat COMP-KDEL construct shown in (A) (SEQ ID NO:16).

FIGURE 3. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of mouse

thrombospondin 3 trimerization domain (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:17), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased stability via disulfide bonds), the mouse TSP3 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the mouse TSP3-KDEL construct shown in (A) (SEQ ID NO:18), indicating the translation start site (circled) and termination site (boxed).

FIGURE 4. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of mouse thrombospondin 3 trimerization domain (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:19), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased stability via disulfide bonds), the mouse TSP3 trimerization domain (overlined, including an additional sub-sequence GEQT at the 5' end relative to FIGURE 3B), the camel IgG linker domain (overlined

and underlined) and KDEL. (C-D) Nucleic acid sequence of the mouse TSP3-KDEL construct shown in (A) (SEQ ID NO:20), indicating the translation start site (circled) and termination site (boxed).

FIGURE 5. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of *Xenopus* thrombospondin 4 trimerization domain (TSP4); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:21), indicating the leader/signal peptide (underlined) plus linker (represented by the amino acids -GSS-), the sub-sequence GDCC, the *Xenopus* TSP4 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the *Xenopus* TSP4-KDEL construct shown in (A) (SEQ ID NO:22), indicating the translation start site (circled) and termination site (boxed).

FIGURE 6. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (in this example from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A)

(SEQ ID NO:23), indicating the leader/signal peptide (underlined) plus linker (represented by the amino acids -GSS-), the sub-sequence GDCC, the human COMP pentamerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human COMP-KDEL construct shown in (A) (SEQ ID NO:24), indicating the translation start site (circled) and termination site (boxed).

FIGURE 7. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human phospholamban (PLB); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:25), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human PLB pentamerization domain (overlined, residues critical for pentamer formation marked by a dot), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human PLB-KDEL construct shown in (A) (SEQ ID NO:26), indicating the translation start site (circled) and termination site (boxed).

FIGURE 8. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human thrombospondin 3 (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the

nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:27), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human TSP3 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human TSP3-KDEL construct shown in (A) (SEQ ID NO:28), indicating the translation start site (circled) and termination site (boxed).

FIGURE 9. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human thrombospondin 4 (TSP4); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (**) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:29), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human TSP4 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human TSP4-KDEL construct shown in (A) (SEQ ID NO:30), indicating the translation start site (circled) and termination site (boxed).

FIGURE 10. (A) Schematic representation of a nucleic acid molecule encoding a KDEL inhibitor protein having (i) a cleavable signal peptide from mouse BiP; (ii) a myc-tag; (iii) an N-linked glycosylation sequence; (iv) the oligomerization domain of the rat cartilage oligomerization protein; (iv) a camel IgG linker domain; and (v) the carboxy terminal sequence KDEL. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:34), indicating the leader/signal peptide (underlined), myc-tag, N-linked glycosylation sequence,

linker (represented by amino acids -GSS-), the sub-sequence GDCC, the rat COMP domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the KDEL construct shown in (A) (SEQ ID NO:35), indicating the translation start site (circled) and termination site (boxed).

5

5. DETAILED DESCRIPTION OF THE INVENTION

For purposes of clarity of presentation and not by way of limitation, the detailed description of the invention is divided into the following subsections:

- (i) KDEL receptor inhibitor proteins; and
- (ii) uses of KDEL receptor inhibitors.

10

5.1. KDEL RECEPTOR INHIBITOR PROTEINS

The present invention provides for a protein comprising a plurality of amino acid sequences which bind to a KDEL receptor (hereafter referred to as a "KDELr inhibitor protein"). By containing a plurality of such sequences, said protein may favorably compete with naturally occurring proteins which bind to the KDEL receptor but which contain a single binding sequence. In preferred, nonlimiting
15 embodiments, the KDELr inhibitor protein is oligomeric, comprising a plurality of subunit proteins each of which comprise, at their carboxy terminal end, a sequence which binds to a KDEL receptor.

The term "KDEL receptor", as used herein, refers to a protein which
20 selectively and specifically binds to a carboxy-terminal KDEL sequence in proteins, and which participates in the redistribution of bound proteins from the Golgi complex to the endoplasmic reticulum. In specific, nonlimiting embodiments, KDEL receptors include the protein encoded by ERD2 in *Saccharomyces cerevesiae* ("ERD2") as well as its human homolog ("hERD2"), as well as structurally and functionally homologous
25 proteins, such as ELP-1, which is 83 percent identical to human ERD-2 (Lewis et al., 1990, Nature 348:162-162; Semenza et al., 1990, Cell 61:1349-1357; Lewis and Pelham, 1992, J. Mol. Biol. 226:913-916; Lewis and Pelham, 1992, Cell 68:353-364; Hsu et al., 1992, Cell 69:625-635).

In specific, nonlimiting embodiments, the amino acid sequence which binds to the KDEL receptor is X-Asp Glu Leu ("XDEL"), where X may be any amino acid, preferably lysine or histidine and most preferably lysine, and is located at the carboxy terminus such that the ultimate C-terminal residue is the leucine of X-Asp-
5 Glu-Leu (KDEL). In specific nonlimiting embodiments of the invention, the carboxy terminal sequence may be Ser-Glu-Lys-Asp-Glu-Leu ("SEKDEL"). Additional amino acid sequences which may bind to the KDEL receptor may be identified by testing the ability of such sequences to compete with Lys-Asp-Glu-Leu (KDEL) for binding to the KDEL receptor in a cell (see, for example, experiments described in Munro and
10 Pelham, 1987, Cell 48:899-907) or under comparable conditions *in vitro*.

Where the KDELr inhibitor protein is oligomeric, it may comprise a plurality of subunits, wherein the subunits may be structurally the same (*i.e.*, a "homooligomer") or different (*i.e.*, a "heterooligomer"). Each subunit may comprise a carboxy terminus which binds to a KDEL receptor, and the remainder of the subunit,
15 or a portion thereof, may permit a means for the association between subunits and the formation of the oligomer. Subunits may be covalently or noncovalently joined together. Where subunits are covalently joined, linkages may result from disulfide bonds, oxidized carbohydrate residues, or crosslinking agents, to name a few nonlimiting examples.

20 In preferred embodiments of the invention, an amino acid sequence which binds to the KDEL receptor may be incorporated as the carboxy terminus in a protein subunit of an oligomeric protein or portion thereof. Suitable known oligomers may include immunoglobulin molecules; especially preferred, however, are smaller oligomeric molecules, including, but not limited to, pentamers formed via the
25 oligomerization domain of a cartilage oligomeric matrix protein ("COMP", which has been used to produce a high avidity binding protein termed a "peptabody", described in Terskikh et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94:1663-1668).

Thus, in specific, nonlimiting examples, the present invention provides for a KDELr inhibitor protein formed via association between a plurality of subunits,
30 each comprising the oligomerization domain of a COMP or a homologous oligomeric protein such as thrombospondin 3 ("TSP3", which is trimeric), thrombospondin 4

("TSP 4", which is trimeric) or phospholamban ("PLB", which is pentameric). As such, the present invention provides for an oligomeric KDELr inhibitor protein comprising a plurality of subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor, for example, a region having, at its carboxy terminus, the XDEL amino acid sequence referred to above. In preferred nonlimiting embodiments of the invention, the region which binds to a KDEL receptor has the amino acid sequence Lys Asp Glu Leu, and the oligomerization domain has an amino acid sequence selected from the following amino acid sequences (Malashkevick et al., 1996, *Science* 274:761-765), or a subfragment or homolog thereof which forms an oligomer under conditions as set forth in Efimov et al., 1994, *FEBS Letts* 341:54-58 and Efimov et al., 1996, *Proteins* 24:259.

(1) COMP (rat, res. 27-72) Gly-Asp-Leu-Ala-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Glu-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO: 1);

(2) COMP (human) Ser-Asp-Leu-Gly-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Asp-Trp-Leu-Arg-Gln-Gln-Val-Arg-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO:2);

(3) TSP3 (mouse) Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:3);

(4) TSP3 (human) Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:4);

(5) TSP4 (human) Gly-Asp-Phe-Asn-Arg-Gln-Phe-Leu-Gly-Gln-Met-Thr-Gln-Leu-Asn-Gln-Leu-Leu-Gly-Glu-Val-Lys-Asp-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Thr-Ser-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID

NO:5);

(6) TSP4 (*Xenopus*) Gly-Asp-Val-Ser-Arg-Gln-Leu-Ile-Gly-Gln-Ile-Thr-Gln-Met-Asn-Gln-Met-Leu-Gly-Glu-Leu-Arg-Asp-Val-Met-Arg-Gln-Gln-Val-Lys-Glu-Thr-Met-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:6); and

(7) PLB (human, residues 26-52) Gln-Lys-Leu-Gln-Asn-Leu-Phe-Ile-Asn-Phe-Cys-Leu-Ile-Leu-Ile-Cys-Leu-Leu-Leu-Ile-Cys-Ile-Ile-Val-Met-Leu-Leu (SEQ ID NO:7).

The foregoing sequences may, for example, be altered by deletion, insertion, or substitution, provided that they remain capable of forming an oligomer under comparable conditions.

KDELr inhibitor proteins may be prepared by any method known in the art, using either chemical synthesis or genetic engineering techniques. Accordingly, the present invention provides for nucleic acids comprising regions encoding a KDELr inhibitor protein of the invention or a subunit thereof, operably linked to suitable elements which facilitate the expression of the protein, and comprised in a nucleic acid vector. Suitable vectors include, but are not limited to, herpes simplex viral based vectors such as pHSV1 (Geller et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:8950-8954); retroviral vectors such as MFG (Jaffee et al., 1993, Cancer Res. 53:2221-2226), and in particular Moloney retroviral vectors such as LN, LNSX, LNCX, LXSN (Miller and Rosman, 1989, Biotechniques 7:980-989) and semliki forest virus ("SFV") vectors; vaccinia viral vectors such as MVA (Sutter and Moss, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10847-10851); adenovirus vectors such as pJM17 (Ali et al., 1994, Gene Therapy 1:367-384; Berker, 1988, Biotechniques 6:616-624; Wand and Finer, 1996, Nature Medicine 2:714-716); adeno-associated virus vectors such as AAV/neo (Mura-Cacho et al., 1992, J. Immunother. 11:231-237); lentivirus vectors (Zufferey et al., 1997, Nature Biotechnology 15:871-875; pET 11a, pET3a, pET11d, pET3d, pET22d, and pET12a (Novagen); plasmid AH5 (which contains the SV40 origin and the adenovirus major late promoter); pRC/CMV (InVitrogen, Carlsbad, CA); pCMU II (Paabo et al., 1986, EMBO J. 5:1921-1927); pZipNeo SV (Cepko et al., 1984, Cell 37:1053-1062); pSR α (DNAX, Palo Alto, CA);

pBK-CMV (Stratagene, La Jolla, CA); pCDNA3 (InVitrogen, Carlsbad, CA); and pCDNA1 (InVitrogen, Carlsbad, CA). Where the KDELr inhibitor protein is oligomeric, oligomers may be formed *in vivo* or *in vitro*. An example of conditions which would produce such oligomers *in vitro* would be a room temperature solution including oxidized and reduced glutathione at concentrations of 10 mM and 2 mM, respectively (Efimov et al., 1994, FEBS Let. 341:54-58).

Any of the KDELr inhibitor proteins described above may be introduced into a cell, wherein the cell is synthesizing, has synthesized, or will synthesize a protein which would tend to bind to a KDEL receptor and hence be returned to the endoplasmic reticulum (hereafter referred to as an "ER protein"), where it is desired that the KDEL receptor inhibitory protein promote the secretion of the ER protein. A KDELr inhibitor protein may be introduced into the cell by any means known in the art, including the introduction of a gene encoding the KDELr inhibitor protein or microvesicles comprising KDELr inhibitor protein.

Where the KDELr inhibitor protein is genetically introduced, a nucleic acid encoding said KDELr inhibitor protein should also encode a signal sequence linked to said protein which targets the KDELr inhibitor protein to the endoplasmic reticulum. Nonlimiting examples of signal sequences which may be used include the mouse BiP signal peptide shown in FIGURES 1-5, the adenovirus E3/19kd signal peptide (Anderson et al., 1991, J. Exp. Med. 174:489-492) as shown in FIGURES 6-9, the human pre-prolactin signal peptide or the human pre-proinsulin signal peptide.

Where the KDELr inhibitor itself is to be introduced into a cell, it may be linked to one or more sugar residue to facilitate its uptake into endosomes, for example, via the insulin receptor (Krupp and Lane, 1982, J. Biol. Chem. 257:1372-1377), the mannose 6 phosphate receptor or the asialoglycoprotein receptor (Berg et al., 1982, Exp. Cell Res. 148:319-330) and Wu, 1988, Biochem. 27:887-892; Plank et al., 1992, Bioconjugate Chem. 3:533-539), or linked to another biological molecule, such as folate (for uptake via the folate receptor; Wang et al., 1995, Proc. Natl. Acad. Sc. U.S.A. 92:3318), insulin (for uptake via the insulin receptor; Hockett et al., 1990, Biochem. Pharmacol. 40:253) or transferrin (for uptake via the transferrin receptor; Kuhn et al., 1984, Cell 37:95-103; McClelland et al., 1984, Cell 39:267-274; Morgan

et al., 1978, *Blood* 52:1219-1228; Karin and Mintz, 1981, *J. Biol. Chem.* 256:3245-3252; Octave et al., 1983, *Trends Biochem. Sci.* ("TIBS") 8:217-220; Newman et al., 1982, *TIBS* 7:397-400; Zenke et al., 1990, *Proc. Natl. Acad. Sci. U.S.A.* 87:3655). As a nonlimiting specific example, FIGURE 10 depicts a KDEL inhibitor protein

5 comprising an N-linked glycosylation site. The consensus site for N-glycosylation is NXT or NXS. The sequence NST, comprised in the protein depicted in FIGURE 10, is used as an optimized sequence for glycosylation in a context related to KDEL peptide (Misenbock and Rothman, 1995, *J. Cell Biol.* 129:309-319; see also Kim et al., 1998, *Proc. Natl. Acad. Sci. U.S.A.* 95:2997-3002). The molecule depicted in FIGURE 10

10 also comprises a myc-tag sequence (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu; SEQ ID NO: 36), which may be used as a marker for localization of the protein using, for example, monoclonal antibody 9E10.

Where nucleic acid encoding the KDELr inhibitor protein is to be introduced into a cell, it may be comprised in any suitable vector, including, but not

15 limited to, herpes simplex viral based vectors such as pHSV1 (Geller et al., 1990, *Proc. Natl. Acad. Sci. U.S.A.* 87:8950-8954); retroviral vectors such as MFG (Jaffee et al., 1993, *Cancer Res.* 53:2221-2226), and in particular Moloney retroviral vectors such as LN, LNSX, LNCX, and LXSX (Miller and Rosman, 1989, *Biotechniques* 7:980-989); vaccinia viral vectors such as MVA (Sutter and Moss, 1992, *Proc. Natl.*

20 *Acad. Sci. U.S.A.* 89:10847-10851); adenovirus vectors such as pJM17 (Ali et al., 1994, *Gene Therapy* 1:367-384; Berker, 1988, *Biotechniques* 6:616-624; Wand and Finer, 1996, *Nature Medicine* 2:714-716); adeno-associated virus vectors such as AAV/neo (Mura-Cacho et al., 1992, *J. Immunother.* 11:231-237), and naked DNA

25 vectors (International Application Publication No. WO 94/21797, by Merck et al.; International Application Publication No. WO 90/11092, by Vical et al.; United States Patent No. 5,589,466; United States Patent 5,580,859).

A KDELr inhibitor protein of the invention may be further modified, for example, to improve its half-life or activity or to alter its immunogenicity (i.e., increase or decrease the subtype of immunity elicited). In particular embodiments of

30 the invention, a KDELr inhibitor protein of the invention may be conjugated to a second molecule, such as polyethylene glycol, or to an antigenic peptide. As a specific

nonlimiting example of the latter, an antigenic peptide may be linked to one or more iterations of the N-linked glycosylation tripeptide sequence Asn-X-Thr comprised in a KDELr inhibitor protein. Expression of such a KDELr inhibitor protein/antigenic peptide complex in a lectin resistant cell line, such as 15B Chinese Hamster Ovary (CHO) cells or 1021 CHO cells, may be used to produce a mannosylated or sialylated KDELr inhibitor protein which may saturate endogenous KDEL receptors and be secreted into the surrounding culture medium. Secreted and non-secreted forms of this protein may be comprised in a vaccine fomulation; by virtue of its mannosylation or sialylation, the KDELr inhibitor protein would be favored for uptake via incorporation into endosomes (Engering et al., 1997, Eur. J. Immunol. 27:2417-2425). In further embodiments of the invention, a KDELr inhibitor protien may be linked to another protein molecule as a fusion peptide or protein. As one nonlimiting example, nucleic acid encoding a KDELr inhibitor protein may be cloned at the 5' or 3' end of another molecule, using, e.g., the BamHI or KpnI restriction sites depicted in FIGURE 1A. As another nonlimiting example, a targeting sequence may be incorporated into the amino terminal region of a KDELr inhibitor protein downstream from a cleavably removed sequence; suitable targeting sequences would include the α_v integrin binding motif Arg-Gly-Asp (RGD) or Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys (SEQ ID NO:33; termed "RGD-4C"; Arap et al., 1998, Science 279:377-380). Alternatively, such a motif could be placed at a more 3' site preceding KDEL.

In a first nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a pentamer of monomeric units, wherein each monomer comprises a COMP pentamerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURE 1A depicts a nucleic acid molecule encoding one such monomeric unit, wherein a cleavable signal peptide is attached, via a linker sequence, to the pentamerization domain of rat COMP, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as, but not limited to, pCDNA3, and used to produce monomers which under normal expression conditions assemble to form the pentameric KDELr inhibitor protein.

In a second nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a trimer of monomeric units, wherein each monomer comprises a mouse thrombospondin 3 (TSP3) trimerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURES 3A and 4A depict nucleic acid molecules encoding one such monomeric unit, wherein a signal peptide is attached, via a linker sequence, to the trimerization domain of mouse TSP3, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as, but not limited to, pCDNA3 and used to produce monomers which under normal expression conditions assemble to form the trimeric KDELr inhibitor protein.

In a third nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a pentamer of monomeric units, wherein each monomer comprises a human COMP pentamerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURE 6A depicts a nucleic acid molecule encoding one such monomeric unit, wherein a signal peptide is attached, via a linker sequence, to the pentamerization domain of human COMP, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as, but not limited to, pCDNA3 and used to produce monomers which under normal expression conditions assemble to form the pentameric KDELr inhibitor protein.

In further related nonlimiting examples of the invention, KDELr inhibitor proteins may be prepared using constructs depicted in FIGURE 7A (using the human phospholamban oligomerization domain to produce pentamers); FIGURE 8A (using the human thrombospondin 3 oligomerization domain to produce trimers); FIGURE 9A (using the human thrombospondin 4 oligomerization domain to produce trimers); and FIGURE 5A (using the *Xenopus* thrombospondin 4 oligomerization domain to produce trimers).

5.2. USES OF KDEL RECEPTOR INHIBITORS

The present invention provides for a number of therapeutic and commercial uses for KDEL receptor inhibitors.

The term "KDEL receptor inhibitor", as used herein, includes but is not limited to the KDELr inhibitor proteins described in the preceding section. Non-protein molecules as well as molecules comprising a majority of non-protein elements are also encompassed by the scope of this term. Such inhibitors share the common property of inhibiting the ability of the KDEL receptor to return proteins containing a ligand sequence for the KDEL receptor to the endoplasmic reticulum. For example, KDEL receptor inhibitors may compete with the ligand sequence for binding with the KDEL receptor (*e.g.*, the oligomeric protein comprising a plurality of such ligand sequences described above), but the term includes inhibitors which act by other mechanisms as well (for example, agents which increase the ability of the KDEL receptor to release its bound proteins).

To identify KDEL receptor inhibitors, the ability of a putative inhibitor compound may be tested *in vivo* for its ability to promote the secretion of proteins which normally tend to bind to the KDEL receptor and be retained in the cell, particularly in the endoplasmic reticulum. This may be accomplished by quantitating the rate and amount of release of one or more such proteins from a cell, tissue, or cell culture in the presence and absence of putative inhibitor and/or at various concentrations of putative inhibitor. As one nonlimiting example, the distribution of a detectably labeled protein may be followed, as was done with a protein marked with an 11 amino acid sequence derived from the human *c-myc* gene in Munro and Pelham, 1987, Cell 48:899-907.

Alternatively, KDEL receptor inhibitors may be identified by testing the ability of putative inhibitors to bind to a KDEL receptor *in vitro*. In nonlimiting embodiments, the ability of such putative KDEL inhibitors to compete with a known KDEL receptor ligand or a known KDEL receptor inhibitor for binding to a KDEL receptor may be tested. As a specific, nonlimiting example, the ability of a putative inhibitor to compete with a KDELr inhibitor protein (as described in the preceding section) for binding to a KDEL receptor may be determined. Such *in vitro* testing may

desirably be performed under conditions which are similar to those found within the cell, for example, see Wilson et al., 1993, J. Biol. Chem. 268:7465-7468). Suitable sources for KDEL receptor include Golgi membrane prepared from rat liver or COS cells expressing the erd2 receptor. Putative inhibitors which appear to function as

5 KDEL receptor inhibitors *in vitro* may then be further evaluated for their ability to inhibit KDEL receptor function *in vivo*.

As set forth above, KDEL receptor inhibitors may be used to increase the secretion of a protein which would otherwise tend to be retained in a cell by virtue of the action of the KDEL receptor, when secretion of such protein is desirable.

10 Situations where increased secretion of a protein would be advantageous would include (i) where genetic engineering has introduced a gene encoding a protein, hereafter referred to as an "exogenous protein", into a cell, and it desirable that the exogenous protein is secreted (*e.g.*, as a specific nonlimiting example, where the exogenous protein is a heat shock protein); and (ii) where it is desirable to increase the

15 secretion of a protein which has not been introduced by genetic engineering but which occurs in the cell either normally or as a result of a disease process such as infection or malignancy (*e.g.*, a native heat shock protein or a viral protein), hereafter referred to as an "endogenous protein".

Accordingly, the present invention provides for a method of increasing

20 the secretion of an exogenous or endogenous protein by a cell, wherein the protein comprises a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the protein from the cell relative to the secretion of the protein in the absence of the KDEL receptor inhibitor.

25 In one series of nonlimiting embodiments, where it is desirable that an exogenous protein is secreted, a nucleic acid encoding both the exogenous protein as well as a KDELr inhibitor protein (as part of the same, or distinct, nucleic acid constructs), may be introduced into a cell. According to this specific embodiment, the introduction of two distinct constructs, one encoding the desired protein and the other

30 encoding the KDELr inhibitor protein, may be used to more accurately target the secretion of the desired protein to a particular subset of cells or tissues (that is to say,

the introduced protein will be selectively secreted when both constructs are present). In related embodiments, nucleic acid encoding the desired protein and/or the KDELr inhibitor protein may be placed under the control of tissue specific or inducible promoter/enhancer elements.

- 5 In a second series of nonlimiting embodiments, where it is desirable that an endogenous protein is secreted, a KDEL receptor inhibitor, for example a KDELr inhibitor protein, may be introduced into a cell of a subject in need of such treatment, either by administration of the KDEL receptor inhibitor itself or via a nucleic acid encoding a KDELr inhibitor protein. As an example of such
- 10 embodiments, heat shock proteins are known to associate with antigenic peptides to form complexes which induce an immune response to the bound peptides, and, since certain heat shock proteins tend to be selectively retained in the endoplasmic reticulum via the KDEL receptor system (including BiP and gp96), the present invention may be used to promote secretion of the antigenic heat shock protein
- 15 complexes and thereby to induce or increase an immune response to a target antigen. The target antigen may be associated with an infectious disease or a cancer, including antigens associated with neoplasia such as sarcoma, lymphoma, leukemia, melanoma, carcinoma of the breast, carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix, uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma,
- 20 and astrocytoma, antigens associated with defective tumor suppressor genes such as p53; antigens associated with oncogenes such as ras, src, erbB, fos, abl, and myc; antigens associated with infectious diseases caused by a bacterium, virus, protozoan, mycoplasma, fungus, yeast, parasite or prion; and antigens associated with an allergy or autoimmune disease. Examples of sources of antigens associated with infectious
- 25 disease include, but are not limited to, a human papilloma virus (see below), a herpes virus such as herpes simplex or herpes zoster, a retrovirus such as human immunodeficiency virus 1 or 2, a hepatitis virus, an influenza virus, a rhinovirus, a respiratory syncytial virus, a cytomegalovirus, an adenovirus, *Mycoplasma pneumoniae*, a bacterium of the genus *Salmonella*, *Staphylococcus*, *Streptococcus*,
- 30 *Enterococcus*, *Clostridium*, *Escherichia*, *Klebsiella*, *Vibrio*, or *Mycobacterium*, and a protozoan such as an amoeba, a malarial parasite, and *Trypanosoma cruzi*.

Specific, nonlimiting examples of human papilloma virus antigenic peptides which may serve as target antigens according to the invention are:

Leu-Leu-Leu-Gly-Thr-Leu-Asn-Ile-Val (SEQ ID NO: 8);

Leu-Leu-Met-Gly-Thr-Leu-Gly-Ile-Val (SEQ ID NO: 9);

5 Thr-Leu-Gln-Asp-Ile-Val-Leu-His-Leu (SEQ ID NO: 10);

Gly-Leu-His-Cys-Tyr-Glu-Gln-Leu-Val (SEQ ID NO: 11); and

Pro-Leu-Lys-Gln-His-Phe-Gln-Ile-Val (SEQ ID NO: 12).

Accordingly, the present invention relates to a method for promoting the release of a heat shock protein/antigenic peptide complex from a cell, where the
10 heat shock protein contains a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the complex from the cell relative to the secretion of the complex in the absence of the KDEL receptor inhibitor. Where the KDEL receptor inhibitor is a protein, it may be administered as a protein or as a nucleic acid encoding
15 said KDELr inhibitor protein (using "genetic vaccination techniques" including, but not limited to, techniques whereby "naked DNA" encoding the KDELr inhibitor protein is administered to a subject).

In related embodiments, the present invention further provides for a method of inducing or increasing an immune response to a target antigen, comprising
20 administering an effective amount of a KDEL receptor inhibitor, where the target antigen forms a complex with a heat shock protein and the heat shock protein contains a ligand sequence which binds to a KDEL receptor. The target antigen may be an endogenous antigen or may be introduced, either by an encoding nucleic acid or in peptide form. Similarly, the heat shock protein may be an endogenous heat shock
25 protein or may be introduced by gene therapy techniques.

In a specific, nonlimiting embodiment, the present invention envisions the use of a KDEL receptor inhibitor which may be used to boost immunity in a subject in need of such treatment; examples would include a subject at risk of developing a cancer in view of a genetic predisposition or carcinogen exposure, or a
30 subject at risk for developing infection in view of a compromised immune system and/or pathogen exposure. Under circumstances where the antigen has not yet been

identified, immunity may be induced toward endogenous antigen(s). Where target antigen(s) is (are) known, a KDEL receptor inhibitor may be administered in conjunction with a target antigen, which may be comprised in a vaccine administered by any standard route (*e.g.*, subcutaneously, intramuscularly, intranasally, etc.). An orally administered KDEL receptor inhibitor may be particularly advantageous.

Because systemic administration of a KDEL receptor inhibitor may be expected to transiently induce widespread release of proteins normally retained in the endoplasmic reticulum, it may be desirable to administer a KDEL receptor inhibitor having a short half-life at intervals which minimize any toxic effects, for example, but not by way of limitation, one dose every two weeks for a month. Alternatively, a KDEL receptor inhibitor may be locally administered to a site containing endogenous antigen (for example, a malignant tumor or infected tissue) or a site containing exogenous antigen (for example, but not by way of limitation, a site wherein nucleic acid encoding target antigen has been administered).

The present invention further provides for a non-human transgenic animal carrying, as a transgene, in all or a subpopulation of the cells of the animal, nucleic acid encoding a exogenous KDELr inhibitor protein (as distinct from KDEL-bearing proteins normally present in the animal), operably linked to a promoter sequence. In preferred nonlimiting embodiments of the invention, the promoter is an inducible promoter. Such a transgenic animal may be used to study the effects of promoting the secretion of an endogenous or exogenously introduced protein of interest.

Where a protein comprising a ligand sequence for a KDEL receptor is being commercially produced, a KDEL receptor inhibitor of the invention may be used to promote secretion of the protein and therefore facilitate its manufacture.

Accordingly, the present invention provides for compositions comprising a KDEL receptor inhibitor, or a nucleic acid encoding a KDEL receptor inhibitor, in a suitable pharmaceutical carrier. Such compositions may further comprise a target antigen or a nucleic acid encoding a target antigen or a precursor of a target antigen which is processed in a cell to yield a target antigen, a nucleic acid encoding a heat shock protein, a cytokine which promotes the activity of the immune

system, such as interleukin 2 and/or alpha interferon, and/or an agent which facilitates protein secretion, such as monensin.

For illustrative purposes only, specific, nonlimiting embodiments of the invention may be practiced as follows.

5 1. Expression And Purification Of Recombinant rCOMP-KDELr Inhibitor Proteins.

Rat COMP-KDELr inhibitor protein encoded by a pet 11-derived plasmid prepared using the construct depicted in FIGURE 1A, under the control of the T7 promoter, may be expressed in *E. coli* BL21 (DE3) cells, according to the method
10 described in Efimov et al., 1994, FEBS Letts. 341:54-58. Vector-containing bacteria may be cultured in shaker flasks at 37°C to an OD₆₀₀ of approximately 0.5 - 0.6, and then 1.0 mM isopropyl β-D-thiogalactoside may be added per liter of culture to induce protein synthesis. After further incubation for about four hours at 30°C, bacterial cells may be harvested by centrifugation at 8000 x g for 15 minutes at 4°C. Bacterial pellets
15 may then be resuspended in 20 ml TE buffer (20mM Tris-HCl, pH 8.0, 1mM EDTA) containing 0.1 mg/ml lysozyme, and then incubated at 25°C or room temperature for about 30 minutes. Alternatively, bacterial cells may be lysed using a cell disruptor such as Emulsiflex C-5 (Avestin, Ontario, Canada). The resulting cell lysate may be incubated with 0.1 mg/ml DNAase I for 15 minutes at 25°C (room temperature) and
20 then centrifuged at 23,000 x g at 4°C for fifteen minutes to remove insoluble material. These conditions may also be used for subsequent centrifugations. Two milliliters of 30 percent w/v streptomycin sulfate solution may be mixed with the resulting supernatant and the mixture may be incubated on ice for 15 minutes. The resulting precipitate may be removed by centrifugation and ammonium sulfate may be added to
25 the supernatant to about 36 percent saturation, and the solution may be incubated on ice for about 15 minutes to produce an ammonium sulfate/protein precipitate. The ammonium sulfate/protein precipitate may then be collected by centrifugation as set forth above. The pellet obtained by centrifugation may be resuspended in 2 ml TE buffer and applied to a 10 ml hydroxylapatite column (BioRad, DNA grade), pre-equilibrated with 10 mM sodium phosphate, pH 7.6. The column may be washed with
30 the pre-equilibration buffer having an increasing phosphate gradient, and the flow-

through protein fraction, which would be expected to contain mainly the recombinant rCOMP-KDELr inhibitor protein, may be collected. Analogous methods may be used to purify KDELr inhibitor protein expressed in 15B CHO cells or insect cells.

Oligomerization of the recombinantly expressed protein may be
5 achieved as follows, using a method as described in Efimov et al., 1994, FEBS Letts. 341:54-58. Purified KDELr inhibitor protein may be substantially (preferably completely) reduced by incubation with a 100-fold molar excess of dithiothreitol (DTT) for about 30 minutes at 37°C, followed by precipitation with 50 percent ammonium sulfate, followed by centrifugation as set forth above. The resulting pellet
10 may be resuspended in 0.2 M Tris-HCl, pH 8.8, 0.2 M NaCl, 1 mM EDTA to a final protein concentration of 1.5 mg/mL. The protein may be oxidized at room temperature by addition of oxidized and reduced glutathione to final concentrations of 10 mM and 2 mM respectively over a period of about 14 hours. The oxidized protein may then be separated from glutathione by HPLC or dialysis. The correctly folded pentamer may
15 also be purified by reverse phase chromatography on a C4 column.

The KDELr inhibitor protein may also be oligomerized by the method described in Jaenicke and Rudolph, 1989, in Creighton et al., *Protein Structure: a practical approach*. IRL Press Oxford, pp. 208-209, wherein the protein may be first reduced by incubation for 2 hours in 0.1 M DTT, 6 M guanidine hydrochloride, 1 mM
20 EDTA and 0.1 M Tris-HCl, pH 8.3, followed by acidification and dialysis overnight at 4°C against 0.01 M HCl, and then refolded for about 16 hours at 16°C in an oxido-shuffling system containing 0.3 mM cystine and 3 mM cysteine, 1 mM EDTA and 0.1 M Tris-HCL, pH 8.3. The protein may subsequently be purified by HPLC, lyophilized and stored at 4°C.

25 2. Testing The Ability of KDEL Receptor Inhibitor To Bind To KDEL Receptor.

The ability of KDEL receptor inhibitors of the invention to bind to KDEL receptor may be tested *in vitro* using alkali-washed Golgi membranes. Such membranes may be prepared from livers of freshly sacrificed rats using the methods
30 described by Tabas and Kornfeld, 1979, J. Biol. Chem. 254:11655-11663, or from

cultured cells expressing erd 2 receptors in their Golgi membranes. For example, harvested liver or cultured cells may be dounced and used to prepare a 1500 x g postnuclear supernatant, which may then be spun at 100,000 x g to recover a crude membrane fraction. The resulting crude membranes may then be washed with 100 mM Na₂CO₃ at 4°C, pelleted by centrifugation at 100,000 x g, and then resuspended in 10 mM HEPES-KOH, pH 7.5 to produce alkali-washed Golgi membrane.

The alkali-washed Golgi membrane may then be used in a binding assay as described by Wilson et al., 1993, J. Biol. Chem. 268:7465-7468 to determine whether a putative KDEL receptor inhibitor binds to the erd 2 (KDEL) receptor. The ability of a putative KDEL receptor inhibitor to bind to the erd 2 receptor may be determined by measuring the ability of the inhibitor to compete with a detectably labeled peptide which binds the erd 2 receptor, such as Tyr-Thr-Ser-Glu-Lys-Asp-Glu-Leu (SEQ ID NO:31) or Leu-Asn-Tyr-Phe-Asp-Asp-Glu-Leu (SEQ ID NO:32) for receptor binding. Such peptides may, for example, be radioiodinated by incubation with 1 mCi of [¹²⁵I] iodide for one minute in the presence of 2.4 mg/ml of chloramine T (BDH Chemicals, Ltd.) quenched and the iodinated peptides may be separated on a Sephadex G-10 column (Pharmacia) as described in Harlow and Lane, 1988, in *Antibodies: a laboratory manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY. The binding assay buffer may contain 20 mM NaCl, 250 mg/ml bovine serum albumin, 50 mM sodium or potassium cacodylate or citrate, pH 5.0-5.5, MES (2-[N-morpholino]ethane sulfonic acid) or a mixture of succinate and PIPES (piperazine-N,N'-bis[2-ethanesulfonic acid) at the same molarity. Putative KDEL receptor inhibitor at various concentrations, total membrane protein (for example 0.5-1.0 µg), radiolabeled peptide (for example, 0.1-0.5 ng peptide having 1 x 10⁵ cpm) and alkali-washed Golgi membrane at 2-4 percent w/v may be incubated in (e.g., 25 µl) binding assay buffer at 4°C for about 20 minutes, and then centrifuged in a microfuge (at about 15,800 x g) at 4°C for 5 minutes, and the amount of labeled peptide present in the pellet may be determined. An observed decrease in bound labeled peptide with increasing concentrations of putative KDEL receptor inhibitor indicates that the putative KDEL receptor inhibitor is binding to the erd 2 receptor.

3. Introduction Of rCOMP/KDELr Inhibitor Protein Into Tumor Cells.

A 375 base pair Hind III - Xho I fragment of a partial gene construct encoding a cleavable signal peptide (such as the signal peptide from the murine heat shock protein BiP) at the 5' end linked to the rat COMP pentamerization domain
5 followed by the camel IgG domain (see FIGURE 1A) may be synthesized (for example, by a commercial entity such as Oligos, Etc., Inc., Oregon). The resulting fragment may be cloned into a mammalian expression vector such as pCDNA3 by standard techniques (see, for example, Sambrook et al., 1990, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY), using the Hind
10 III - Xho I restriction sites and transformed into TOP10F' competent cells (which may be obtained from InVitrogen, Inc.). The sequences of the resulting plasmid, rCOMP/pCDNA3 may be verified by dideoxy sequencing (Sanger et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467) using Sequenase 2.0 (United States Biochemical).

15 A 72 base pair double-stranded KDEL-containing oligonucleotide may then be annealed at the 3' end of rCOMP-pCDNA3 using the Kpn I- Eco RI restriction endonuclease site (see FIGURE 1A) to generate rCOMP-KDELr inhibitor/pCDNA3. This construct may then be verified by dideoxynucleotide sequencing.

20 The construct rCOMP-KDELr inhibitor/pCDNA3 may then be expressed, for example, in a tumor cell line such as CMS-5. CMS-5 is a methylcholanthrene-induced fibrosarcoma of BALB/c origin, shown to be devoid of viral antigens (DeLeo et al., 1977, J. Exp. Med. 146:720-734). CMS-5 cells may be adapted to culture and grown in DMEM medium (Gibco Life Technologies, Inc.)
25 supplemented with 10% fetal calf serum (FCS). Transfection may be carried out using lipofectamine, according to the manufacturer's instructions (Gibco-BRL Life Technologies). Briefly, 2µg of cDNA and 6µL of lipofectamine may be diluted separately into 100 µL serum-free medium (OPTI-MEM® I Reduced Serum medium, Gibco-BRL Life Technologies). The two solutions may then be mixed and incubated
30 at room temperature for about 45 minutes to allow the formation of DNA-liposome complexes. 800 µL of OPTI-MEM® may be added to the resulting complexes, mixed,

and overlaid onto rinsed cells. After an approximately six hour incubation period at 37°C, one milliliter of growth medium containing 20% FCS may be added. Fresh medium may be added to the cells 24 hours post-transfection. Stable clones may be selected by adding 800 µg/ml geneticin (Gibco-BRL Life Technologies) to the cells
5 72 hours later. The selection medium may be changed about every three days.

Colonies of stably transfected cells may be screened for expression of rCOMP/KDEL_r inhibitor proteins using antiserum raised against bovine COMP (Hedbom et al., 1992, J. Biol. Chem. 264:6898-6905). This antibody has been shown to stain rat COMP under both nonreducing as well as reducing conditions (Morgelin et al., 1992, J. Biol.
10 Chem. 267:6137-6141).

Stably transfected tumor cells produced in this manner may be utilized in a number of ways. For example, they may be used to determine whether increased secretion of a particular protein, normally retained by the KDEL receptor, may effect the tumorigenicity of the cells. In one specific nonlimiting example, they may be used
15 to determine whether the secretion of an endogenous heat shock protein is increased and whether the increased secretion of endogenous protein decreases the tumorigenicity of the cells (*e.g.*, stably transfected CMS-5 cells described above may be inoculated into CB6F-1/J mice). In another specific nonlimiting example, stably transfected tumor cells may further be transfected with nucleic acid encoding an
20 exogenous protein, and it may be determined whether increased secretion of the exogenous protein by the tumor cells decreases their tumorigenicity.

Various references are cited herein, the contents of which are hereby incorporated by reference in their entireties.

CLAIMS

1. An oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor.
- 5 2. The KDEL receptor inhibitor protein of claim 1, wherein the region which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-Leu.
3. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain is a pentamerization domain.
4. The KDEL receptor inhibitor protein of claim 2, wherein the
10 oligomerization domain is a pentamerization domain.
5. The KDEL receptor inhibitor protein of claim 3, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.
6. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain is derived from a thrombospondin protein.
- 15 7. The KDEL receptor inhibitor protein of claim 5, wherein the pentamerization domain has the amino acid sequence Gly-Asp-Leu-Ala-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Glu-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO: 1).
- 20 8. The KDEL receptor inhibitor protein of claim 5, wherein the pentamerization domain has the amino acid sequence Ser-Asp-Leu-Gly-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Asp-Trp-Leu-Arg-Gln-Gln-Val-Arg-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-

Cys-Gly (SEQ ID NO:2).

9. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-
5 Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:3).

10. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-
10 Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:4).

11. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Asp-Phe-Asn-Arg-Gln-Phe-Leu-Gly-Gln-Met-Thr-Gln-Leu-Asn-Gln-Leu-Leu-Gly-Glu-Val-Lys-Asp-Leu-Leu-
15 Arg -Gln-Gln-Val-Lys-Glu-Thr-Ser-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:5).

12. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Asp-Val-Ser-Arg-Gln-Leu-Ile-Gly-Gln-Ile-Thr-Gln-Met-Asn-Gln-Met-Leu-Gly-Glu-Leu-Arg-Asp-Val-Met-Arg-
20 Gln-Gln-Val-Lys-Glu-Thr-Met-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:6).

13. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain has the amino acid sequence Gln-Lys-Leu-Gln-Asn-Leu-Phe-Ile-Asn-Phe-Cys-Leu-Ile-Leu-Ile-Cys-Leu-Leu-Leu-Ile-Cys-Ile-Ile-Val-Met-Leu-Leu
25 (SEQ ID NO:7).

14. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 1.

15. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 2.

5 16. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 3.

17. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 4.

10 18. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 5.

19. An isolated nucleic acid encoding a KDEL receptor inhibitor of
claim 6.

15 20. A method of increasing the secretion of a protein by a cell, wherein
the protein comprises a ligand sequence which binds to a KDEL receptor, comprising
exposing the cell to a KDEL receptor inhibitor at a concentration which increases the
secretion of the protein from the cell relative to the secretion of the protein in the
absence of the KDEL receptor inhibitor.

20 21. The method of claim 20, wherein the KDEL receptor inhibitor is an
oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits,
wherein each subunit comprises an oligomerization domain and has, at its carboxy
terminus, a region which binds to a KDEL receptor.

22. The method of claim 21, wherein the region of the KDEL inhibitor
protein which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-

Leu.

23. The method of claim 21, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

5 24. The method of claim 22, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

25. The method of claim 23, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

26. The method of claim 21, wherein the oligomerization domain is derived from a thrombospondin protein.

10 27. The method of claim 24, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

28. The method of claim 22, wherein the oligomerization domain is derived from a thrombospondin protein.

15 29. A method for promoting the release of a heat shock protein/antigenic peptide complex from a cell, where the heat shock protein contains a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the complex from the cell relative to the secretion of the complex in the absence of the KDEL receptor inhibitor.

20 30. The method of claim 29, wherein the KDEL receptor inhibitor is an oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor.

31. The method of claim 30, wherein the region of the KDEL inhibitor protein which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-Leu.

32. The method of claim 30, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

33. The method of claim 31, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

34. The method of claim 32, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

35. The method of claim 30, wherein the oligomerization domain is derived from a thrombospondin protein.

36. The method of claim 33, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

37. The method of claim 31, wherein the oligomerization domain is derived from a thrombospondin protein.

38. A method of inducing or increasing an immune response to a target antigen, comprising administering, to a subject in need of such treatment, an effective amount of a KDEL receptor inhibitor, where the target antigen forms a complex with a heat shock protein and the heat shock protein contains a ligand sequence which binds to a KDEL receptor.

39. The method of claim 38 wherein the target antigen is an endogenous antigen.

40. The method of claim 38 wherein the target antigen is an antigen which has been introduced into the subject.

41. The method of claim 38 wherein the heat shock protein is an endogenous heat shock protein.

5 42. The method of claim 38 wherein the heat shock protein has been introduced into the subject by the administration of a nucleic acid encoding the heat shock protein.

43. A non-human transgenic animal carrying a transgene encoding the KDEL receptor inhibitor protein of claim 1 operably linked to a promoter sequence.




FIG. 1A

SIGNAL CLEAVAGE SITE

MGKFTVVAALLLLGAVRAE-CSS-

LGCDLA-PQMLRELQETNAALQDVRELLRQQVKEITFLKNTVMECDACG-MQPARTPGTS-

PQPQKPQPQPQPQPKPEPE-GTGSSE-KDEL

FIG. 1B

2/30




FIG. 1C

3/30

FIG. 1D




FIG. 2A

SIGNAL CLEAVAGE SITE

MGKFTVAAALLLGAVRAE-GSS-

LGCC - PQLRELQETNAALQDVRELLRQQVKEITFLKNTVMECDACG - MQPARTPGTS -

PQQPKPQQPQQPQQPKPQQPKPEPE-GTGSSE-KDEL

FIG. 2B

5/30




FIG. 2C

6/30




FIG. 2D

7/30




FIG. 3A

SIGNAL CLEAVAGE SITE

MCKFTVVAALLLGAVRAE-GSS-

LCGDCC-KALVTQTLTFNQILVELRDDIRDQVKEMSLIRNTIMECQVCC-

PQPQKPQPQPQPQPQPQPQPQPQPQP-GTGSSE-KDEL

FIG. 3B

8/30





FIG. 3C

9/30



SEEK D E L

FIG. 3D

10/30




FIG. 4A

SIGNAL CLEAVAGE SITE

MCKFTVVAALLLGAVRAE-GSS-

LGGDCC-GEQTKALVTQLTLFNQILVELRDDIRDQVKEMSLIRNTIMECQVCG-

PQQPKPQQPQQPQQPKPQQPKPEPE-GTGSSE-KDEL

FIG. 4B

11/30




FIG. 4C

SUBSTITUTE SHEET (RULE 26)

Diagram illustrating the DNA sequence CATCTCGAG with restriction sites NsiI, XhoI, and SclI. The sequence is shown as a horizontal line with vertical tick marks indicating the positions of the restriction sites. NsiI is at position 1, XhoI at position 2, and SclI at position 3. The sequence ends at position 369.

FIG. 4D

13/30




FIG. 5A

SIGNAL CLEAVAGE SITE

M G K F T V A A A L L L G A V R A E - G S S -

L G G D C C - G D V S R Q L I G Q I T Q M N Q M L G E L R D V M R Q Q V K E T M F L R N T I A E C Q A C G -

P Q Q P K P Q Q P Q Q P K P Q Q K P E P E - G T G S S E - K D E L

FIG. 5B

14/30




FIG. 5C

P P Q P K P Q P Q P Q P Q P Q P Q P Q P

15/30

CCCGAAGGTACCGGATCATCAGAAAGATGAGTTGTTAGCGCGCGCCAGCAATTC CATATG

Acc65I KpnI Eco52I EcoRI Ppu10I BfrBI NdeI

P E G T G S S E K D E L .

:ATAC

Diagram illustrating the restriction enzyme sites for NsiI, XhoI, and SclI on the DNA sequence CATCTCGAG. The NsiI site is located at the beginning of the sequence, followed by the XhoI site, and then the SclI site. The sequence ends with the codon CAG, which is labeled as 369.

FIG. 5D

16/30




FIG. 6A

SIGNAL CLEAVAGE SITE

MRYMILGLLAALAAVCSAAKK-GSS-

LGCDCC-SDLGPQMLRELQETNAALQDVDRDLRQQVREITFLKNTVMECDACG-

PQPQPKPQPQPKPQPQPKPEPE-GTGSSE-KDEL

FIG. 6B

17/30




FIG. 6C

P Q P K P Q P Q P Q P Q P Q P Q P Q P E

Acc65I
 KpnI
 Eco52I
 EcoRI
 Ppu10I
 BfrBI
 NdeI
 C C C G G A A G G T A C C G G A T C A G A A A A G A T G A G T T G T A G C C G C C G C A G A A T T C C A T A T C
 360

PE G T G S S E K D E L

18/30

19/30




FIG. 7A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A L A A V C S A A K K - G S S -

L G G D C C - Q K L Q N L F I N F C I L I C L L I C I I V M L L -

P Q P Q K P Q P Q P Q P Q P Q P K P E P E - G T G S S E - K D E L

• RESIDUES CRITICAL FOR PENTAMER FORMATION

FIG. 7B

20/30




FIG. 7C

21/30





FIG. 7D






FIG. 8A

SIGNAL CLEAVAGE SITE

MRYMILGLLALAAVCSAAKK-GSS-

LGGCC-GEQTKALVTQLTLFNQILVELRDDIRDQVKEMSLIRNTIMECQVCG-

PQPQPKPQQPQPPKPEPE-GTGSSE-KDEL

FIG. 8B

23/30




FIG. 8C

CCGCAGCCGAACCGCAGCCGCA**G**CCGCCAGCCGCAGCCGGAAACCGCACCGCAAACCGGA
+-----+-----+-----+-----+-----+-----+
ACGCAGCCGAACCGCAGCCGCA**G**CCGCCAGCCGCAGCCGGAAACCGCACCGCAAACCGGA
+-----+-----+-----+-----+-----+-----+

P Q P K P Q P Q P Q P Q P Q P Q P Q P E

1

Acc65I
 KpnI
 Eco52I
 EcoRI
 Ppu10I
 B1rBI
 NdeI
 C C G G A A G G T A C C G G A T C A G A A A A G A T G A G T T G T A G C C G C C G C A G A A T T C C A T A T C
 360

PE C T C S S E K D E L

Diagram illustrating the DNA sequence CATCTCGAG with restriction sites NsiI, XhoI, and SclI. The sequence is shown as a horizontal line with tick marks indicating the positions of the restriction sites. NsiI is at position 1, XhoI is at position 4, and SclI is at position 7. The sequence ends at position 369.

FIG. 8D

25/30




FIG. 9A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A A V C S A A K K - G S S -

L G G D C C - G D F N R Q F L G Q M T Q L N Q L L G E V K D L L R Q Q V K E T S F L R N T I A E C Q A C G -

P Q P Q K P Q P Q P Q P Q P K P Q P K P E P E - G T G S S E - K D E L

FIG. 9B

26/30




FIG. 9C

27/30

CCGCAGCCGAAACCGCAGCCGCGCAGCCGCGAAGCCGAGCCGGAACCCGGA 300

P Q P K P Q P Q P Q P Q P Q P K P Q P K P E

+

CCGGAAGGTACCGGATCATCAGAAAGATGAGTTGTAGCGCGCCGAGAAATTCATAIC 360

P E C T C S S E K D E L

NsiI
XhoI
SciI
CATCTCGAG 369

FIG. 9D




FIG. 10A




FIG. 10B





FIG. 10C

30/30



SEQUENCE LISTING

<110> Rothman, James
 Mayhew, Mark
 Hoe, Mee

5 <120> KDEL RECEPTOR INHIBITORS

<130> 31488

<160> 36

<170> FastSEQ for Windows Version 3.0

10 <210> 1
 <211> 46
 <212> PRT
 <213> rat

<400> 1

15 Gly Asp Leu Ala Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala
 1 5 10 15
 Ala Leu Gln Asp Val Arg Glu Leu Leu Arg Gln Gln Val Lys Glu Ile
 20 25 30
 Thr Phe Leu Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly
 20 35 40 45

<210> 2
 <211> 46
 <212> PRT
 <213> human

25 <400> 2
 Ser Asp Leu Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala
 1 5 10 15
 Ala Leu Gln Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg Glu Ile
 20 25 30

2

Thr Phe Leu Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly
 35 40 45

<210> 3

<211> 46

5

<212> PRT

<213> mouse

<400> 3

Gly Glu Gln Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln
 1 5 10 15

10 Ile Leu Val Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met
 20 25 30

Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly
 35 40 45

<210> 4

15

<211> 46

<212> PRT

<213> human

<400> 4

Gly Glu Gln Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln
 1 5 10 15

20 Ile Leu Val Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met
 20 25 30

Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly
 35 40 45

25

<210> 5

<211> 46

<212> PRT

<213> human

<400> 5

30 Gly Asp Phe Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln
 1 5 10 15

3

Leu Leu Gly Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr
 20 25 30
 Ser Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly
 35 40 45

5 <210> 6
 <211> 46
 <212> PRT
 <213> xenopus laevis

 <400> 6
 10 Gly Asp Val Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln
 1 5 10 15
 Met Leu Gly Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr
 20 25 30
 Met Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly
 15 35 40 45

<210> 7
 <211> 27
 <212> PRT
 <213> human

20 <400> 7
 Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys
 1 5 10 15
 Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu
 20 25

25 <210> 8
 <211> 9
 <212> PRT
 <213> human papilloma virus

 <400> 8
 30 Leu Leu Leu Gly Thr Leu Asn Ile Val
 1 5

4

<210> 9

<211> 9

<212> PRT

<213> human papilloma virus

5

<400> 9

Leu Leu Met Gly Thr Leu Gly Ile Val

1

5

<210> 10

<211> 9

10

<212> PRT

<213> human papilloma virus

<400> 10

Thr Leu Gln Asp Ile Val Leu His Leu

1

5

15

<210> 11

<211> 9

<212> PRT

<213> human papilloma virus

<400> 11

20

Gly Leu His Cys Tyr Glu Gln Leu Val

1

5

<210> 12

<211> 9

<212> PRT

25

<213> human papilloma virus

<400> 12

Pro Leu Lys Gln His Phe Gln Ile Val

1

5

<210> 13

5

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

5

<223> chimeric rat comp

<400> 13

Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1 5 10 15
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Leu Ala Pro Gln Met
 10 20 25 30
 Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu
 35 40 45
 Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val
 50 55 60
 15 Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr
 65 70 75 80
 Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro
 85 90 95
 Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys
 20 100 105 110
 Asp Glu Leu
 115

<210> 14

<211> 387

25

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric rat COMP-KDEL

<400> 14

30

aagcttacca tgggaaagtt cactgtgggtg gcggcggcgt tgctgctgct gggcgcggtg
 60
 cgggcccagg gatccagcct ggggtggagac ctagcccccac agatgcttcg agaactccag

120
 gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc
 180
 accttctctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc
 5 240
 cccggtacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa
 300
 ccgcagccga aaccggaacc ggaaggtacc ggatcatcag aaaaagatga gttgtaggcg
 360
 10 gccgcagaat tccatatgca tctcgag
 387

<210> 15
 <211> 115
 <212> PRT
 15 <213> Artificial Sequence
 <220>
 <223> chimeric rat COMP-KDEL

<400> 15
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 20 1 5 10 15
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Pro Gln Met
 20 25 30
 Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu
 35 40 45
 25 Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val
 50 55 60
 Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr
 65 70 75 80
 Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro
 30 85 90 95
 Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys
 100 105 110
 Asp Glu Leu
 115

7

<210> 16

<211> 387

<212> DNA

<213> Artificial Sequence

5

<220>

<223> chimeric rat COMP-KDEL

<400> 16

aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg
60

10

cgggccgagg gatccagcct ggggtggagac tgttggtccac agatgcttcg agaactccag
120

gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc
180

15

accttcctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc
240

cccgggtacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa
300

ccgcagccga aaccggaacc ggaaggtacc ggatcatcag aaaaagatga gttgtaggcg
360

20

gccgcagaat tccatatgca tctcgag
387

<210> 17

<211> 105

<212> PRT

25

<213> Artificial Sequence

<220>

<223> chimeric mouse TSP3-KDEL

<400> 17

Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala

30

1 5 10 15
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Lys Ala Leu

20

25

30

8

Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val Glu Leu Arg Asp
 35 40 45
 Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile Arg Asn Thr Ile
 50 55 60
 5 Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro Lys Pro Gln Pro
 65 70 75 80
 Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly
 85 90 95
 Thr Gly Ser Ser Glu Lys Asp Glu Leu
 10 100 105

<210> 18

<211> 357

<212> DNA

<213> Artificial Sequence

15

<220>

<223> chimeric mouse TSP3-KDEL

<400> 18

aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg
 60
 20 cgggccgagg gatccagcct ggggtggagac tggtgtaagg cattggtcac ccagctcacc
 120
 ctcttcaacc agatcctagt ggagcttcgg gacgacatcc gagaccaggt gaaggaaatg
 180
 tcaatcatcc ggaacaccat catggagtgt caggtgtgcg gtccgcagcc gcagccgaaa
 25 240
 ccgcagccgc agccgcagcc gcagccgaaa ccgcagccga aaccggaacc ggaaggtacc
 300
 ggatcatcag aaaaagatga gttgtaggcg gccgcagaat tccatatgca tctcgag
 357

30

<210> 19

<211> 109

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric mouse TSP3-KDEL

<400> 19

5 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1 5 10 15
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln
 20 25 30
 Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val
 35 40 45
 10 Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile
 50 55 60
 Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro
 65 70 75 80
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro
 15 85 90 95
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu
 100 105

<210> 20

<211> 369

20

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric mouse TSP3-KDEL

<400> 20

25 aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg
 60
 cgggcccagg gatccagcct ggggtggagac tgttggtggg agcagaccaa ggcattggtc
 120
 acccagctca cctcttcaa ccagatccta gtggagcttc gggacgacat ccgagaccag
 30 180
 gtgaaggaaa tgctactcat ccggaacacc atcatggagt gtcaggtgtg cggtcgcgag
 240
 ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa

10

300

ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatattg

360

catctcgag

5

369

<210> 21

<211> 109

<212> PRT

<213> Artificial Sequence

10

<220>

<223> chimeric *Xenopus laevis* TSP4-KDEL

<400> 21

Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala

1

5

10

15

15

Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Val

20

25

30

Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln Met Leu Gly

35

40

45

Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr Met Phe Leu

20

50

55

60

Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro

65

70

75

80

Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro

85

90

95

25

Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu

100

105

<210> 22

<211> 369

<212> DNA

30

<213> Artificial Sequence

<220>

<223> chimeric *Xenopus laevis* TSP4-KDEL

11

<400> 22
 aagcttacca tgggaaagtt cactgtggtg gcggcggtg tgctgctgct gggcgcggtg
 60
 cgggcccagg gatccagcct ggggtggagac tgttggtggtg acgtcagcag acagttgatt
 5 120
 ggccagataa cccaaatgaa tcagatgctg ggagagctcc gagatgtcat gagacagcag
 180
 gtgaaagaga ccatgttctt gagaaacacc attgcagaat gccaggcctg tggcccgcag
 240
 10 ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa
 300
 ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatag
 360
 catctcgag
 15 369

<210> 23
 <211> 109
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> chimeric human COMP-KDEL

<400> 23
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser
 1 5 10 15
 25 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Ser Asp Leu
 20 25 30
 Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln
 35 40 45
 Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg Glu Ile Thr Phe Leu
 30 50 55 60
 Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly Pro Gln Pro Gln Pro
 65 70 75 80
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro
 85 90 95

12

Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu

100

105

<210> 24

<211> 372

5

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric human COMP-KDEL

<400> 24

10 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccggc agtctgcagc

60

gctgccaaaa aaggatccag cctgggtgga gactgttggt cagacctggg cccgcagatg

120

cttcgggaac tgcaggaaac caacgcggcg ctgcaggacg tgcgggactg gctgcggcag

15

180

caggtcaggg agatcacgtt cctgaaaaac acggtgatgg agtgtgacgc gtgcggggccg

240

cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg

300

20 gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat

360

atgcattctcg ag

372

<210> 25

25

<211> 90

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric human PLB-KDEL

30

<400> 25

Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser

```

1           5           10           15
Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gln Lys Leu
20           25           30
Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu
5           35           40           45
Ile Cys Ile Ile Val Met Leu Leu Pro Gln Pro Gln Pro Lys Pro Gln
50           55           60
Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu
65           70           75           80
10 Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu
85           90

```

```

15      <210> 26
        <211> 315
        <212> DNA
        <213> Artificial Sequence

```

<220>
<223> chimeric human PLB-KDEL

```

20      <400> 26
      aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgcggc agtctgcagc
      60
      gctgccaaaa aaggatccag cctgggtgga gactgttgtc aaaagctaca gaatctattt
      120
      atcaatttct gtctcatctt aatatgtctc ttgctgatct gtatcatcgt gatgcttctc
      180
25      ccgcagccgc agccgaaacc gcagccgcag ccgcagccgc agccgaaacc gcagccgaaa
      240
      ccggaaccgg aaggtaccgg atcatcagaa aaagatgagt tgtaggcggc cgcagaattc
      300
      catatgcata tcgag
30      315

```

```
<210> 27
<211> 109
<212> PRT
```


14

<213> Artificial Sequence

<220>

<223> chimeric human TSP3-KDEL

<400> 27

5 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser
 1 5 10 15
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln
 20 25 30
 Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val
 10 35 40 45
 Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile
 50 55 60
 Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro
 65 70 75 80
 15 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro
 85 90 95
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu
 100 105

<210> 28

20 <211> 372

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric human TSP3-KDEL

25 <400> 28

aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgcggc agtctgcagc
 60
 gctgccaaaa aaggatccag cctgggtgga gactgttggtg gggagcagac caaggcattg
 120
 30 gtcaccagc tcaccctctt caaccagatc ctagtggagc ttcgggacga catccgagac
 180
 caggtgaagg aaatgtcact catccggaac accatcatgg agtgtcaggt gtgcgggtccg

15

240

cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg

300

gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat

5 360

atgcatctcg ag

372

<210> 29

<211> 109

10

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric human TSP4-KDEL

<400> 29

15

Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser

1

5

10

15

Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Phe

20

25

30

Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln Leu Leu Gly

20

35

40

45

Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr Ser Phe Leu

50

55

60

Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro

65

70

75

80

25

Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro

85

90

95

Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu

100

105

<210> 30

30

<211> 372

<212> DNA

<213> Artificial Sequence

16

<220>

<223> chimeric human TSP4-KDEL

<400> 30

5 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgcggc agtctgcagc
60
gctgccaaaa aaggatccag cctgggtgga gactgttggtg gggactttaa ccggcagttc
120
ttgggtcaaa tgacacaatt aaaccaactc ctgggagagg tgaaggacct tctgagacag
180
10 caggttaagg aaacatcatt tttgcgaaac accatagctg aatgccaggc ttgcggtccg
240
cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg
300
gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat
15 360
atgcatctcg ag
372

<210> 31

<211> 8

20 <212> PRT

<213> unknown

<400> 31

Tyr Thr Ser Glu Lys Asp Glu Leu

1 5

25 <210> 32

<211> 8

<212> PRT

<213> unknown

<400> 32

30 Leu Asn Tyr Phe Asp Asp Glu Leu

1 5

17

<210> 33

<211> 9

<212> PRT

<213> unknown

5

<400> 33

Cys Asp Cys Arg Gly Asp Cys Phe Cys

1

5

<210> 34

<211> 134

10

<212> PRT

<213> Artificial Sequence

<220>

<223> KDEL/myc

<400> 34

15

Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala

1

5

10

15

Val Arg Ala Glu Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu

20

25

30

Tyr His Pro Asn Ser Thr Cys Gly Ser Ser Leu Gly Gly Asp Cys Cys

20

35

40

45

Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp

50

55

60

Val Arg Glu Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys

65

70

75

80

25

Asn Thr Val Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr

85

90

95

Pro Gly Thr Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln

100

105

110

Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser

30

115

120

125

Ser Glu Lys Asp Glu Leu

130

18

<210> 35

<211> 444

<212> DNA

<213> Artificial Sequence

5

<220>

<223> KDEL-myc

<400> 35

aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg
60

10

cgggccgagg gatccgaaca aaaacttatt tctgaagaag acttgtacca cccaaactca
120

acatgcggat ccagcctggg tggagactgt tgccacaga tgcttcgaga actccaggag
180

15

actaatgcgg cgctgcaaga cgtgagagag ctcttgcgac agcaggtcaa ggagatcacc
240

ttcctgaaga atacggtgat ggaatgtgac gcttgcgga tgcagcccg cgcaccccc
300

ggtactagtc cgcagccgca gccgaaaccg cagccgcagc cgcagccgca gccgaaaccg
360

20

cagccgaaac cggaaccgga aggtaccgga tcatacagaaa aagatgagtt gtaggcggcc
420

gcagaattcc atatgcatct cgag
444

<210> 36

25

<211> 10

<212> PRT

<213> human myc tag

<400> 36

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu

30

1

5

10

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/17147

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/52 C07K14/78 C07K14/47 A61K38/17
A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 06828 A (SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH) 27 February 1997 (1997-02-27) page 5, line 20 - line 25 page 10, line 32 -page 11, line 12 -----	29, 37-42
A	WO 98 18943 A (CIBA GEIGY AG ;KAJAVA ANDREY (CH); UNIV LAUSANNE (CH); CRAMERI RET) 7 May 1998 (1998-05-07) the whole document especially page 2 -----	1-8, 14-19, 21-28

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 January 2000

Date of mailing of the international search report

24/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 17147

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-37, insofar as an in vivo method is envisaged, and claims 38-42 are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the KDEL receptor inhibitor
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 99/17147

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9706828 A	27-02-1997	AU 6849396 A	12-03-1997
		AU 6898496 A	12-03-1997
		AU 712907 B	18-11-1999
		AU 6952896 A	12-03-1997
		CA 2229543 A	27-02-1997
		CA 2229595 A	27-02-1997
		EP 0851764 A	08-07-1998
		EP 0888053 A	07-01-1999
		HU 9802819 A	29-03-1999
		HU 9901672 A	28-09-1999
		WO 9706685 A	27-02-1997
		WO 9706821 A	27-02-1997
WO 9818943 A	07-05-1998	AU 6909298 A	22-05-1998
		EP 0938571 A	01-09-1999